. home.aspx


Clinical genetics: a part of Pharma’s DNA

October 14, 2019 / REGINA GABITOVA

Genetic testing has become an increasingly buoyant area for deal making in recent years. While the pharma industry has been experiencing price pressure and low R&D productivity, the recent market ambition for “Precision Medicine”1 has driven interest and growth in clinical genetics and M&A in the genetics market has been following a strong upward trajectory.